N
Nathalie Baize
Publications - 8
Citations - 4903
Nathalie Baize is an academic researcher. The author has contributed to research in topics: Carboplatin & Lung cancer. The author has an hindex of 4, co-authored 7 publications receiving 4305 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Nathalie Baize,Isabelle Monnet,Laurent Greillier,Margaux Geier,Hervé Lena,H. Janicot,Alain Vergnenegre,Jacky Crequit,R. Lamy,Jean-Bernard Auliac,Jacques Letreut,Hervé Le Caer,Radj Gervais,Eric Dansin,A. Madroszyk,Patrick-Aldo Renault,Gwenaelle Le Garff,Lionel Falchero,Henri Berard,Roland Schott,Patrick Saulnier,Christos Chouaid,Groupe Français de Pneumo-Cancérologie – investigators +22 more
TL;DR: The results suggest that carboplatin plus etoposide rechallenge can be considered as a reasonable second-line chemotherapy option for patients with sensitive relapsed small-cell lung cancer.
Journal ArticleDOI
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
Teresa Moran,J. Wei,M. Cobo,X. Qian,Manuel Domine,Z. Zou,Isabel Bover,Liang Wang,Mariano Provencio,L. Yu,Imane Chaib,C. You,B. Massuti,Y. Song,A. Vergnenegre,H. Lu,Guillermo Lopez-Vivanco,W. Hu,Gilles Robinet,J. Yan,A. Insa,X. Xu,Margarita Majem,X. Chen,R. de las Peñas,Niki Karachaliou,M.A. Sala,Q. Wu,Dolores Isla,Y. Zhou,Nathalie Baize,F. Zhang,J. Garde,P. Germonpre,S. Rauh,H. ALHusaini,Maria Sanchez-Ronco,Ana Drozdowskyj,Jose Javier Sanchez,Carlos Camps,B. Liu,Rafael Rosell,B. Colinet,J. De Greve,H. Chen,J. Du,Y. Gao,J. Hu,W. Kong,L. Li,R. Li,X. Li,J. Liu,W. Ren,L. Wen,X. Xiao,J. Yang,M. Yang,Y. Yang,J. Yin,X. Yue,J. Zhang,L. Zhu,P. Bombaron,Christos Chouaid,Eric Dansin,P. Fournel,G. Fraboulet,Radj Gervais,S. Hominal,S. Kahlout,H. Lecaer,Hervé Lena,J. LeTreut,C. Locher,Olivier Molinier,Isabelle Monnet,G. Oliviero,R. Schoot,P. Thomas,G. Berchem,H. Al Husaini,Francisco Aparisi,Edurne Arriola,I. Ballesteros,Isidoro Barneto,R. Bernabé,Ana Blasco,Joaquim Bosch-Barrera,V. Calvo de Juan,Enric Carcereny,Silvia Catot,Enriqueta Felip,M.-R. García-Campelo,C. García-Girón,Ramon Garcia-Gomez,R. Garcia-Sevila,A. Gasco,J. Gil,Jose-Luis Gonzalez-Larriba,S. Hernando-Polo,E. Jantus,B. Jiménez,Pilar Lianes,R. López-López,A. López-Martín,Jose Antonio Macias,J.L. Marti-Ciriquian,R. Montoyo,Daniela Morales-Espinosa,Miguel Angel Moreno,Cinta Pallares,Marta Parera,R. Perez-Carrión,R. Porta,Noemí Reguart,F. Rosillo,J.M. Sanchez,I. Sullivan,J. Terrasa,Jose Manuel Trigo,Javier Valdivia,Nuria Viñolas,Santiago Viteri,M. Botia-Castillo,José-Luis Mate,M. Perez-Cano,Josep Ramírez,B. Sanchez-Rodriguez,Miquel Taron,M. Tierno-Garcia,E. Mijangos,J. Ocaña,E. Pereira,J. Shao,X. Sun,R. O'Brate +136 more
TL;DR: The BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible and it is expected that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches.
Journal ArticleDOI
Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).
Teresa Moran,Manuel Cobo,Manuel Domine,Maria Sanchez-Ronco,Isabel Bover,Mariano Provencio,Bartomeu Massuti,Alain Vergnenegre,Guillermo Lopez-Vivanco,Gilles Robinet,Amelia Insa,Margarita Majem,Ramon De Las Penas,María Ángeles Sala,Dolores Isla,Nathalie Baize,J. Garde,Imane Chaib,Carlos Camps,Rafael Rosell +19 more
TL;DR: A prospective, randomized phase III trial comparing noncustomized cis/doc with customized therapy in metastatic NSCLC p and a parallel phase II study is being carried out in China under the auspices of the SLCG.
Journal ArticleDOI
A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.
Ahmed Idbaih,François Ducray,Roger Stupp,Nathalie Baize,Olivier Chinot,John de Groot,J Guyotat,Adam M. Sonabend,Philippe Menei,Henry Dufour,Jeffrey S. Weinberg,Carole Desseaux,Michael Canney,Charlotte Schmitt,Alexandre Carpentier +14 more
TL;DR: Significant Gd enhancement was observed after more than 90% of sonication sessions, suggesting effective BBB disruption and carboplatin enhancement in patients with recurrent glioblastoma.